Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445301 | 0.81 | IKBKE (0.46) | MIFCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20873080 | 0.78 | NPC1 (0.54) | PRKCZCYP11B2CYP11B1CYP3A4CYP2D6 | |
| SCHEMBL1445121 | 0.75 | CYP11B2 (0.50) | PRKCZCYP11B2CYP11B1CYP3A4CYP2D6 | |
| SCHEMBL20873066 | 0.74 | PRKCZ (0.64) | PRKCZCYP11B2CYP11B1CYP3A4CYP2D6 | |
| SCHEMBL12676858 | 0.73 | CYP11B2 (0.51) | PRKCZCYP11B2CYP11B1CYP3A4CYP2D6 | |
| SCHEMBL19443925 | 0.72 | PRKCZ (0.58) | MIFPRKCZCYP11B2CYP11B1CYP3A4 | |
| SCHEMBL1445057 | 0.71 | MIF (0.50) | MIFCYP1A2HTR2C | |
| SCHEMBL1444767 | 0.70 | MIF (0.44) | MIFCYP11B2 | |
| SCHEMBL15624007 | 0.70 | ERN1 (0.45) | PRKCZCYP11B2CYP11B1CYP3A4CYP2D6 | |
| SCHEMBL1445161 | 0.69 | MIF (0.56) | MIFCYP3A4CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | claimed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | claimed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | claimed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9155790-B2 | Methods and compositions for modulating ocular damage | University of Lousiville Research Foundation, Inc. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011146824-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | MIF, MSR1, CCL2 | MIF 1/4885PRKCZ 3641/4885CYP11B2 408/4885 |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | MIF, MMP1, CXCL12 | MIF 1/4885PRKCZ 1297/4885CYP11B2 3192/4885 |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | MIF 1/4885PRKCZ 3451/4885CYP11B2 330/4885 |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | MIF 1/4885PRKCZ 3451/4885CYP11B2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.